Pluristyx and Solesis Release New 3D Stem Cell Transfection Kit to Improve Efficiency and Reduce Toxicity

Key findings

• Pluristyx and Solesis have launched a 3D transfection kit for induced pluripotent stem cells (iPSCs) in suspension culture.
• The kit combines 3D-adapted iPSCs, GFP mRNA, and transfection reagents in a thaw-and-use format.
• The companies say the workflow is designed to improve transfection efficiency while reducing cytotoxicity in 3D iPSC aggregates.

Pluristyx and Solesis announced the commercial launch of the PluriForm™-GFP-3D Transfection Kit, a product designed for mRNA transfection of induced pluripotent stem cells (iPSCs) grown in 3D suspension culture (cells grown as aggregates rather than attached to a surface).

Why 3D iPSC transfection is tricky

Transfecting iPSCs in suspension can be difficult due to low efficiency, high cytotoxicity (cell toxicity), and damage to aggregated cells. Pluristyx says the kit is intended to address these issues by pairing pre-expanded, 3D-adapted, high-density iPSCs with mRNA that is pre-complexed to a proprietary transfection reagent.

According to the companies, the kit is a “three-in-one” system that includes cells, synthetic mRNA, and associated reagents in a thaw-and-use configuration.

“This kit represents a significant leap forward for the field of 3D pluripotent cell culture and organoid research,” said Dr. Priya Baraniak, Chief Commercial and Development Officer of Pluristyx. “In partnering with Solesis, we integrated their cutting-edge transfection reagent directly into our Ready-to-Differentiate® (RTD®) cell workflow resulting in nearly 100% transfection efficiency without need for further optimization.  This enables researchers to skip months of development and rapidly generate reproducible results”.

What’s included (and what it’s designed to do)

• Unmatched, nearly 100% mRNA delivery directly to suspension-cultured iPSCs at the time of aggregate formation.
• Ready-to-Differentiate, high-density iPSCs provided with pre-complexed GFP-mRNA and optimized media.
• PluriGlow™-GFP-3D reagent, which the company says helps maintain consistent formulation and reduce cytotoxicity.

“We are proud to see our transfection technology incorporated within this breakthrough product,” said Marc Hendriks, Vice President, Corporate Development at Solesis. “The PluriForm-GFP-3D kit exemplifies the strength of our collaboration with Pluristyx, combining our material science expertise with their biological leadership to provide tools that align with the next generation of manufacturing and research. This launch marks the beginning of a long-term partnership dedicated to delivering a robust portfolio of enabling technologies”.

The kit is available now, you can request information here.

Want to keep up on regenerative medicine? Get the weekly newsletter here.